We also tested for the first time ex vivo whether therapeutic concentrations of FLX, a selective serotonin reuptake inhibitor (SSRI) known to elevate TGF-β1 in rodents (Torrisi et al., 2019), could rescue TGF-β1 concentrations in the culture medium of PBMCs from individuals with DS. The gene discussed is TGFB1; the disease is Dravet syndrome.